CN105503870A - 神经激肽-1拮抗剂的静脉内制剂 - Google Patents

神经激肽-1拮抗剂的静脉内制剂 Download PDF

Info

Publication number
CN105503870A
CN105503870A CN201510830177.9A CN201510830177A CN105503870A CN 105503870 A CN105503870 A CN 105503870A CN 201510830177 A CN201510830177 A CN 201510830177A CN 105503870 A CN105503870 A CN 105503870A
Authority
CN
China
Prior art keywords
compound
formulation
hemolysis
solutol
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510830177.9A
Other languages
English (en)
Chinese (zh)
Inventor
J.万
P.古普塔
D.蒙泰思
S.巴塔查亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN105503870A publication Critical patent/CN105503870A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201510830177.9A 2009-08-14 2010-08-12 神经激肽-1拮抗剂的静脉内制剂 Pending CN105503870A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23412909P 2009-08-14 2009-08-14
US61/234129 2009-08-14
CN201080046905.2A CN102573475B (zh) 2009-08-14 2010-08-12 神经激肽-1拮抗剂的静脉内制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080046905.2A Division CN102573475B (zh) 2009-08-14 2010-08-12 神经激肽-1拮抗剂的静脉内制剂

Publications (1)

Publication Number Publication Date
CN105503870A true CN105503870A (zh) 2016-04-20

Family

ID=43586486

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510830177.9A Pending CN105503870A (zh) 2009-08-14 2010-08-12 神经激肽-1拮抗剂的静脉内制剂
CN201080046905.2A Expired - Fee Related CN102573475B (zh) 2009-08-14 2010-08-12 神经激肽-1拮抗剂的静脉内制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080046905.2A Expired - Fee Related CN102573475B (zh) 2009-08-14 2010-08-12 神经激肽-1拮抗剂的静脉内制剂

Country Status (15)

Country Link
US (2) US9101615B2 (enExample)
EP (2) EP2464230B1 (enExample)
JP (2) JP5860399B2 (enExample)
KR (1) KR101834577B1 (enExample)
CN (2) CN105503870A (enExample)
AU (1) AU2010282483B2 (enExample)
BR (1) BR112012003263A2 (enExample)
CA (1) CA2770403C (enExample)
ES (1) ES2609640T3 (enExample)
IL (1) IL217942A0 (enExample)
MX (1) MX336071B (enExample)
RU (2) RU2642234C2 (enExample)
SG (2) SG178403A1 (enExample)
TW (2) TWI498329B (enExample)
WO (1) WO2011019911A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789154A (zh) * 2016-08-03 2019-05-21 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170838A1 (en) * 2006-04-05 2011-05-30 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
NZ571693A (en) 2006-04-05 2011-12-22 Opko Health Inc Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
TW201605852A (zh) * 2013-09-26 2016-02-16 美國禮來大藥廠 新穎化合物及其製備ｔａｕ造影劑及ｔａｕ造影調配物之用途
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アプレピタントのエマルジョン製剤
BR112017018620A2 (pt) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. método de administração de tradipitanto, e, tradipitanto.
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
EP3411013A1 (en) * 2016-02-01 2018-12-12 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
CN109963583B (zh) * 2016-11-21 2023-06-09 珠海贝海生物技术有限公司 罗拉吡坦制剂
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN110996911B (zh) * 2017-06-26 2023-01-17 福多兹制药公司 阿瑞匹坦的纳米微脂囊配制品及其方法和应用
KR20250069704A (ko) 2017-06-30 2025-05-19 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN108703950B (zh) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 一种罗拉吡坦的乳剂注射液
CN109394693A (zh) * 2018-12-25 2019-03-01 广州白云山汉方现代药业有限公司 一种罗拉匹坦乳剂及其制备方法和应用
CN109453115A (zh) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 一种罗拉匹坦静脉注射乳剂及其制备方法和应用
US12421260B2 (en) * 2019-06-28 2025-09-23 Shanghai Shengdi Pharmaceutical Co., Ltd Neurokinin-1 antagonist
EP4125875A1 (en) 2020-04-03 2023-02-08 NeRRe Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
KR20230018485A (ko) 2020-06-02 2023-02-07 네르 쎄라퓨틱스 리미티드 폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제
CN116472048B (zh) * 2020-12-25 2025-02-18 上海盛迪医药有限公司 Nk1拮抗剂前药化合物与5-ht3受体拮抗剂的联用用途
CN118510509A (zh) * 2022-01-12 2024-08-16 江苏恒瑞医药股份有限公司 一种包含神经激肽-1拮抗剂前药化合物的药物组合物
EP4464712A4 (en) * 2022-01-12 2025-07-23 Jiangsu Hengrui Pharmaceuticals Co Ltd CRYSTALLINE FORM OF A NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND
CN119528985A (zh) * 2023-08-28 2025-02-28 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049320B2 (en) * 2001-12-18 2006-05-23 Schering Corporation NK1 antagonists
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
JP3350048B2 (ja) * 1989-07-07 2002-11-25 アンドルシェルシュ・インコーポレイテッド アンドロゲン関連疾患の治療方法
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
ES2141174T3 (es) 1992-10-28 2000-03-16 Merck Sharp & Dohme 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
US5661162A (en) 1992-12-14 1997-08-26 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
WO1995019344A1 (en) 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
NZ302926A (en) 1995-02-28 1998-10-28 Hoechst Marion Roussel Inc Composition for use as antihistamines comprising piperidinoalkanol derivatives and inert ingredients
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
CA2260269A1 (en) 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
AU735760B2 (en) 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
JP3571511B2 (ja) * 1997-11-11 2004-09-29 トーアエイヨー株式会社 経皮吸収製剤
CA2356638A1 (en) 1998-12-23 2000-07-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
EP1185301A1 (en) * 1999-05-24 2002-03-13 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
EP1237874B1 (en) 1999-12-17 2006-02-22 Schering Corporation Selective neurokinin antagonists
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
HUP0303154A3 (en) 2001-02-12 2009-08-28 Teva Pharma New crystal forms of oxcarbazepine and processes for their preparation
ES2291538T3 (es) 2001-11-13 2008-03-01 Schering Corporation Antagonistas de nk1.
ATE358482T1 (de) 2002-07-03 2007-04-15 Schering Corp 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
CA2518836A1 (en) * 2003-03-13 2004-09-30 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
GB0321256D0 (en) 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
ES2295924T3 (es) 2003-10-03 2008-04-16 Pfizer, Inc. Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
SG154443A1 (en) 2004-07-01 2009-08-28 Schering Corp Piperidine derivatives as nk1 antagonists
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
CA2588052A1 (en) * 2004-11-30 2006-06-08 Myriad Genetics, Inc. Therapeutic formulations
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
US20070207201A1 (en) * 2006-03-06 2007-09-06 Wyeth Liquid and Semi-Solid Pharmaceutical Formulations and Processes
NZ571693A (en) * 2006-04-05 2011-12-22 Opko Health Inc Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
SG170838A1 (en) 2006-04-05 2011-05-30 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
CN101110758A (zh) 2006-07-21 2008-01-23 华为技术有限公司 建立紧急会话的方法、系统及代理呼叫会话控制功能
JP2010513222A (ja) 2006-08-07 2010-04-30 スティーフェル ラボラトリーズ インコーポレイテッド 結晶抗真菌化合物
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049320B2 (en) * 2001-12-18 2006-05-23 Schering Corporation NK1 antagonists
CN1897942A (zh) * 2003-12-22 2007-01-17 先灵公司 药用组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789154A (zh) * 2016-08-03 2019-05-21 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂
CN109789154B (zh) * 2016-08-03 2021-05-14 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂

Also Published As

Publication number Publication date
TWI498329B (zh) 2015-09-01
CN102573475B (zh) 2016-01-20
EP2464230B1 (en) 2016-10-05
BR112012003263A2 (pt) 2015-09-22
RU2017145628A (ru) 2019-02-19
RU2012109405A (ru) 2013-09-20
TW201111382A (en) 2011-04-01
MX2012001872A (es) 2012-04-11
AU2010282483A1 (en) 2012-03-01
SG178403A1 (en) 2012-03-29
TW201604195A (zh) 2016-02-01
JP6308991B2 (ja) 2018-04-11
CN102573475A (zh) 2012-07-11
RU2642234C2 (ru) 2018-01-24
EP2464230A1 (en) 2012-06-20
US20110038925A1 (en) 2011-02-17
WO2011019911A1 (en) 2011-02-17
IL217942A0 (en) 2012-03-29
US9101615B2 (en) 2015-08-11
KR101834577B1 (ko) 2018-03-05
KR20120060215A (ko) 2012-06-11
EP3143996A1 (en) 2017-03-22
EP2464230A4 (en) 2013-01-02
MX336071B (es) 2016-01-06
ES2609640T3 (es) 2017-04-21
US20160024092A1 (en) 2016-01-28
JP5860399B2 (ja) 2016-02-16
CA2770403A1 (en) 2011-02-17
SG10201407538WA (en) 2015-01-29
JP2013501806A (ja) 2013-01-17
JP2016041734A (ja) 2016-03-31
AU2010282483B2 (en) 2014-09-04
CA2770403C (en) 2020-09-01

Similar Documents

Publication Publication Date Title
CN102573475B (zh) 神经激肽-1拮抗剂的静脉内制剂
US9339553B2 (en) Liquid compositions of insoluble drugs and preparation methods thereof
US8778364B2 (en) Nanodispersion of a drug and process for its preparation
KR20100112564A (ko) 나노분산액
CA2701789A1 (fr) Nouvelles compositions a base de taxoides
CA3123002A1 (en) Stable formulations of anesthetics and associated dosage forms
AU2014271269B2 (en) Intravenous formulations of neurokinin-1 antagonists
EP3316859B1 (en) Propofol emulsion for parenteral administration
HK1172244B (en) Intravenous formulations of rolapitant
HK1254431B (en) Propofol emulsion for parenteral administration
HK1154502B (en) Preparation method of drug loaded emulsion
HK1154502A1 (en) Preparation method of drug loaded emulsion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160420

RJ01 Rejection of invention patent application after publication